Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lacey Rovinelli

Physician Assistant, Surgical Gainesville, GA Physician Assistant

NPI 1043685613 CMS profile 10781809

200 S Enota Dr Ne Ste 380, Gainesville, GA 30501

Open in the dashboard

General payments

$3,832

147 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lacey Rovinelli of Gainesville, GA is reported in the CMS Open Payments database as having received $3,832 across 147 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $962 38
2024 General $1,209 45
2023 General $766 30
2022 General $586 20
2021 General $309 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lacey Rovinelli
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Lacey Rovinelli were reported at $962. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Lacey Rovinelli Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $309 $111 $36–$285 $132
2022 $586 $126 $44–$350 $149
2023 $766 $137 $47–$355 $160
2024 $1,209 $146 $49–$384 $164
2025 $962 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abiomed $913 20 payments
  2. Atricure, Inc. $848 29 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $463 37 payments
  4. Edwards Lifesciences Corporation $200 9 payments
  5. Maquet Cardiovascular U.S. Sales, L.L.C. $174 7 payments
  6. Becton, Dickinson and Company $107 3 payments
  7. Sanofi-Aventis U.S. LLC $100 1 payment
  8. Ethicon US, LLC $90 3 payments
  9. Philips Electronics North America Corporation $87 2 payments
  10. Corcym Inc $87 3 payments
  11. Other $764 33 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,832 147 payments
Products named General payments · program years 2021–2025
  1. Impella $592 12 payments
  2. LifeVest $463 37 payments
  3. SYNERGY ABLATION SYSTEM $346 12 payments
  4. AtriCure cryoICE cryoSPHERE Cryoablation System $305 10 payments
  5. Vasoview Hemopro 2 $174 7 payments
  6. ATRICURE CRYOICE CRYOABLATION SYSTEM (CRYO2) $149 5 payments
  7. HemoSphere $129 4 payments
  8. ATRICLIP LAA EXCLUSION SYSTEM $110 4 payments
  9. PERCEVAL $87 3 payments
  10. INSPIRIS RESILIA AORTIC VALVE $84 4 payments
  11. Other $1,367 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

452

Median for Physician Assistant: 241

Drug cost

$26,511

Median for Physician Assistant: $4,110

Branded share of claims

19.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 41 $25,046
Amiodarone Hcl Generic 58 $536
Tramadol Hcl Generic 66 $187
Clopidogrel Clopidogrel Bisulfate Brand 28 $146
Atorvastatin Calcium Generic 35 $131
Metoprolol Tartrate Generic 66 $127
Mupirocin Generic 18 $106
Potassium Chloride Generic 35 $89
Furosemide Generic 56 $48
Carvedilol Generic 11 $46

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$9,771

Medicare's payments for the services billed

Medicare patients

69

Average age 72

Services billed

112

20 women, 49 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 72%
Atrial fibrillation 54%
Heart failure 52%
Chronic kidney disease 52%
Diabetes 51%
Arthritis 46%
COPD 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

147 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record